Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients

Published:2023-04-14 Issue:3 Volume:41 Page:411-420
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Tozuka Takehiro,Yanagitani Noriko,Yoshida Hiroshi,Manabe Ryo,Ogusu Shinsuke,Tsugitomi Ryosuke,Sakamoto Hiroaki,Amino Yoshiaki,Ariyasu Ryo,Uchibori Ken,Kitazono Satoru,Seike Masahiro,Gemma Akihiko,Nishio Makoto

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01358-3.pdf

Reference41 articles.

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

2. Sher T, Dy GK, Adjei AA (2008) Small cell lung cancer. Mayo Clin Proc 83(3):355–367

3. Morgensztern D, Ng SH, Gao F et al (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5(1):29–33

4. König D, Savic Prince S, Rothschild SI (2021) Targeted therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) 13(4):804

5. Baggstrom MQ, Stinchcombe TE, Fried DB et al (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2(9):845–853

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP